|
Canada-0-SANDBLASTING कंपनी निर्देशिकाएँ
|
कंपनी समाचार :
- Leyden Labs Raises $70M to Advance its Intranasal Antibody . . .
Leyden Laboratories B V announces it has raised $70M in funding to advance its Mucosal Protection Platform This non-vaccine approach utilizes broadly protective intranasally administered antibodies to free people from the threat of respiratory viruses, such as influenza and coronaviruses
- Leyden Labs secures $70M to advance virus-fighting nasal . . .
Leyden Labs, based at Leiden Bio Science Park, has raised $70 million to develop a new way to fight respiratory viruses Their intranasal antibody technology targets viruses like influenza and coronaviruses at the point of entry—the nasal mucosa—offering a practical, non-vaccine approach to stopping infections early
- Leyden Labs raises $70M to protect against influenza and . . .
Leyden Labs is advancing a novel class of broadly protective nasal sprays, including its PanFlu candidate containing the monoclonal antibody CR9114, which is currently in development for influenza prophylaxis
- Leyden Labs secures $70M to advance intranasal antibody . . .
Leyden Labs has raised $70 million in a funding round led by ClavystBio and Polaris Partners, boosting its efforts to develop intranasal antibody therapies targeting respiratory viruses, including influenza and coronaviruses
- Leyden Labs gets $70M to test if nasal sprays can help . . .
Dutch biotech Leyden Labs raises $70M for nasal sprays against flu and coronavirus
- Leyden Labs Raises $70M in Funding - finsmes. com
Leyden Lab s, a Leiden, the Netherlands-based provider of a mucosal protection platform, raised $70M in funding The round was led by ClavystBio and Polaris Partners with participation from
- Leyden Labs Secures $70M to Advance Nasal Spray Innovations
Amsterdam-based Leyden Labs raised $70M to advance its anti-viral nasal spray pipeline The company acquired Singapore's CoV Biotechnology to bolster pandemic preparedness efforts Its nasal sprays aim to block respiratory viruses at their entry point in the mucosa
|
|